OncoMatch/Clinical Trials/NCT07266441
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07266441 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies JNJ-79635322 for multiple myeloma.
Treatment: JNJ-79635322 — The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Cancer Specialists of North Florida · Jacksonville, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify